An observational study in Lung Cancer, Lung Adenocarcinoma and Lung Squamous Cell Carcinoma, sponsored by RenJi Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-18.
Sponsored by RenJi Hospital · Observational
Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.
Lung cancer is the leading cause of cancer-related death in China. In order to improve prognosis of lung cancer as well as provide new therapeutic targets, the identification of effective biomarkers for the prognosis of lung cancer is of great significance. It has been reported that some small molecules such as lncRNA, circRNA and polypeptides in human plasm have good prospects in diagnosing or evaluating the stage of diseases. In this study, we planned to use multi-omics combined with clinical data to discovery some small molecules that are potential to predict the prognosis of lung cancer patients. In addition, we want to construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. And we hope our study can provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 500 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals aged between 18 and 80 years old. Patients with diagnosis of lung cancer or healthy controls without any history of tumor will be eligible for our enrollment.
Exclusion Criteria:
healthy people
patients diagnosed with lung cancer
Identify some prognostic biomarkers in lung cancer.
1. Our study will identify some biomarkers that can predict the prognosis of lung cancer patients. 2. Our study will construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. 3. Our research will provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.
Time frame: 1 week
Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.
This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RenJi Hospital